Informations générales (source: ClinicalTrials.gov)
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Observational [Patient Registry]
Alexion Pharmaceuticals, Inc. (Voir sur ClinicalTrials)
mars 2013
janvier 2031
02 octobre 2025
Post-marketing safety data on patients treated and untreated with eculizumab or
ravulizumab.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | DEVAUD Edouard | 18/09/2025 17:50:08 | Contacter | ||
Critères
Tous
- Male or female patients of any age, including minors, who have been diagnosed with
aHUS
- Patients with or without an identified complement pathogenic variant or
anti-complement factor antibody
- Able to give written informed consent. Patient or patient's parent/legal guardian
must be willing and able to given written informed consent and the patient (if
minor) must be willing to give written informed assent [if applicable as determined
by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].
- ADAMTS13 > 5%, if performed.
Exclusion Criteria:
- Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli
(STEC).
- Unable to give written informed consent. Patient or patient's parent/legal guardian
unable to give written informed consent. Patient (if minor) unable to give written
informed assent (if applicable as determined by the central Institutional Review
Boards/Independent Ethics Committees [IRB/IEC]).